Share on LinkedInShare on LinkedIn

ARTICLE · 01 FEBRUARY 2023

FDA Harshes The CBD Buzz; Is It High Time For Congress To Step In?

Akin
Akin
Contributor
Akin

Akin

Akin is a global law firm with more than 1,100 lawyers and advisors who pride themselves on...

View firm profile
Explore more from Akin

Yesterday, the U.S. Food and Drug Administration (FDA) announced the conclusion of an internal working group that cannabidiol (CBD) will require a new regulatory pathway.

United StatesCannabis & Hemp

Yesterday, the U.S. Food and Drug Administration (FDA) announced the conclusion of an internal working group that cannabidiol (CBD) will require a new regulatory pathway. The FDA explicitly denied three citizen petitions urging the agency to conduct rulemaking to allow CBD to be marketed as a dietary supplement, determining that the available evidence does not sufficiently demonstrate that CBD can meet the safety standards for dietary supplements or food additives. The FDA stated that it would work with Congress to develop a cross-agency strategy to regulate products containing CBD.

CBD has increasingly been added to food products in recent years, appearing in everything from mints to lattes, despite never being determined to be "generally recognized as safe" (GRAS) for human consumption by the FDA and being an ingredient in an FDA-approved drug.1 CBD, like tetrahydrocannabinol (THC), is a cannabinoid that can be derived from cannabis plants, including hemp. The

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from